Advanced Oncotherapy PLC, a developer of next-generation proton therapy systems for cancer treatment, has provided an update on the publication of its annual report and interim results. The company's shares have been suspended from trading on AIM since June 2023 pending clarification of its financial position. As a result, the company will not be able to publish its 2022 Annual Report by the stipulated deadline of June 30, 2023, and its 2023 Interim Results by the stipulated deadline of September 30, 2023. The company is currently working on its recapitalization plan and securing further funding, including bridge financing to address its immediate financing needs. The company intends to provide a more detailed update on its recapitalization and funding plan in early October 2023. Further announcements on the results will be made at the appropriate time.